2024-01-26 08:00:00
Phase III positive pour AstraZeneca
The British laboratory AstraZeneca communicated new results from phase III evaluating theSummary (durvalumab), associated with transarterial chemoembolization (TACE), and bevacizumab in hepatocellular carcinoma eligible for embolization. The combination reduced the risk of disease progression or death by 23%, compared to TACE alone. In 2022, Imfinzi sold for $2.8 billion.
American green light for J&J
The FDA has granted approval to Balversa (erdafitinib) de Johnson & Johnson (J&J) to treat locally advanced or metastatic urothelial carcinoma and sensitive fibroblast growth factor receptor alterations. In trials, this inhibitor reduced the risk of death by 36% compared to chemotherapy alone. This drug thus becomes the first and only targeted treatment for patients suffering from this type of cancer.
I will tell you
source
Lutathera effective as first intention
During phase III, the Lutathera (lutetium Lu177 endowed) by Novartis, as first-line treatment combined with octreotide, reduced the risk of disease progression or death by 72% in patients with advanced gastroenteropancreatic neuroendocrine tumors. This is the first trial demonstrating the effectiveness of radioligand therapy – a ligand associated with a radioactive particle – as first-line treatment.
Selected for you
1706291666
#pipeline #AstraZeneca #Novartis
